Swiss National Bank Sells 3,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Swiss National Bank trimmed its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 0.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 429,900 shares of the biotechnology company’s stock after selling 3,000 shares during the quarter. Swiss National Bank’s holdings in ADMA Biologics were worth $8,594,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ADMA. Bank of Montreal Can bought a new position in ADMA Biologics in the 2nd quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. boosted its position in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. Castleark Management LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $5,400,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of ADMA Biologics during the 2nd quarter valued at approximately $6,468,000. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ADMA. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Stock Performance

ADMA stock opened at $21.47 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $18.86 and its two-hundred day simple moving average is $14.95. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 76.68 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter last year, the firm posted $0.01 earnings per share. Analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jerrold B. Grossman sold 136,861 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now owns 467,305 shares in the company, valued at approximately $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 185,011 shares of company stock worth $3,255,204 over the last quarter. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.